Overviews of This Study:

This research study involves the use of extensive secondary sources; directories; and databases such as Hoovers, Bloomberg Business, Factiva, and Avention; white papers; annual reports; company house documents; and SEC filings of companies.

For estimating the size of the injectable drug delivery market, the segmental market revenues were obtained from secondary sources through extensive primary interviews. The segment-level markets were then added up to reach the total market size of each segment (Type, Formulation Packaging, Therapeutic Application, Usage Pattern, Site of Administration, Distribution Channel, Facility of Use, and Regions). The injectable drug delivery market size was derived by adding the markets of all these segments. The total market derived through the bottom-up approach was again validated through secondary sources and interviews.

The overall market size derived by the bottom-up approach was used in the top-down procedure to estimate the size of the injectable drug delivery through the percentage splits obtained from secondary and primary research for each product segment

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=150

Major Growth Influencing Factors:

The major factors responsible for the growth of this market are the increasing use of biologics, increase in the prevalence of chronic diseases, increasing occurrence of needlestick injuries, and the benefits of injections (convenience, ease of use, and reduced pain). These factors have increased the demand for devices such as safety syringes, prefilled syringes, and autoinjectors.

Recent Developments:

# In 2016, Gerresheimer extended its partnership with Taisei Medical Co. Ltd. (Japan) with an aim to market its ClearJect syringes and provide technical support to its customers. Furthermore, in collaboration with Taisei Medical, the company intends to expand its COP syringe portfolio by manufacturing a new Gx RTF ClearJect brand by combining ClearJect with its glass RTF (ready-to-fill) concept. This partnership is expected to help the company expand its product portfolio and customer base in the syringes market.

# In 2015, Eli Lilly and Company and Sanford-Burnham Medical Research Institute (U.S.) entered into a collaboration for the development of immunological therapies focusing on lupus, Sjögren's syndrome, inflammatory bowel disease, and other autoimmune disorders. This collaboration will combine the expertise of both organizations to develop novel treatments for these diseases.

# In 2014, Terumo Corporation collaborated with Ypsomed Group (a Switzerland-based injection systems manufacturer). Through this collaboration, the company integrated its prefillable polymer syringe, namely, PLAJEX with YpsoMate (an autoinjector system from Ypsomed). This helped the company strengthen its product offerings in the syringes market.

Global Leading Companies:

The leading players in the market are Becton, Dickinson and Company (U.S.), Baxter International (U.S.), Pfizer (U.S.), Gerresheimer AG (Germany), Schott AG (Germany), Eli Lilly and Company (U.S.), and Terumo Corporation (Japan).

Growth Strategies Adopted by Them:

Companies are focused on organic strategies such as product launches. This strategy helped the market players to build a strong position in the market, which helped in increasing demand of customers and to expand their presence in the global market.

The overall growth strategies adopted from 2013 to 2016 includes acquisition, agreements, collaboration, contracts, expansions, product launches, and partnerships. Companies adopted product launches and approvals to strengthen their customer base. Major players, namely, Becton, Dickinson and Company (U.S.), Baxter International (U.S.), Pfizer (U.S.), Gerresheimer AG (Germany), Schott AG (Germany), Eli Lilly and Company (U.S.), and Terumo Corporation (Japan) adopted product launches and approvals to expand their customer base and strengthen their position in the market.

In November 2016, Becton, Dickinson and Company collaborated with Eli Lilly & Company (U.S.) to launch the FDA-approved BD U-500 Insulin Syringe. This is used by patients using Humulin R U-500 insulin for the treatment of diabetes. This has helped the company enhance its product portfolio for the treatment of diabetes. Further, in January 2016, SCHOTT added new closure systems (rigid caps) to its existing wide portfolio of prefillable syringes (PFS), which offers an easy-to-use twist-off mechanism. This helped the company offer advanced products and strengthen its customer base.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=150

Opportunity: Contraceptive injectable

Over the years, the use of injectable contraceptives has increased significantly. This increased use of injectable contraceptives can mainly be attributed to their high efficacy. Injectable contraceptives are not required to be taken daily; they can be administered once every month or once every three months and are considered to be one of the safer modes of pregnancy prevention. They prevent pregnancy 99% of the time, when administered correctly. Due to these reasons the demand for contraceptive injectables is expected to drive the market in future.

According to Guttmacher Institute, in 2012, around 1,697,000 women used injectables for contraception in the U.S. Noristerat Injection is a reversible method of prescription birth control, which is common in the U.K. and other parts of Europe.

Many new products are being launched in contraceptive injections. For instance; in September 2015, Pfizer Inc. launched Sayana Press, the first injectable contraceptive in the U.K. for administration by self-injection.